G53.0
Conditions
Interventions
Group 1: Basically, every patient recieves three interventions (cross-over). The interval between the experimental settins lasts 14 days.
At first every patient recieves pain baseline measure with QS
Sponsors
Lehrstuhl für Neurophysiologie, Centrum für Biomedizin und Medizintechnik Mannheim, Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsmedizin Mannheim, Universität Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: > 18 years old with a peripheral neuropathic pain (post-herpetic neuralgia) and/or Pinprick-hyperalgesia
Exclusion criteria
Exclusion criteria: Skin damage in the hyperalgesia skin area, non-compliant patients, patients with a major depression (Beck-Depressions-Inventar) exclusion BDI > 18, intake cannabinoids (urin test) and intake of illegal drugs, patients with severe systemic disease (>ASAII)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of the experimentel induced hyperalgesia (LTP) in chronic pain patients. Endpoints are measured with quantitative sensory testing (QST) 30 min and 180 min after application of high-frequency stimulation (HFS), additionally 3 weeks and 9 weeks afterwards. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of chronic pain in patients with postherpetic neuralgia. Endpoints are measured with quantitative sensory testing (QST) 30 min and 180 min after application of high-frequency stimulation (HFS), additionally 3 weeks and 9 weeks afterwards. | — |
Countries
Germany
Contacts
Public ContactJustus;Benjamin Benrath;Gerber
Klinik für Anästhesiologie und Operative IntensivmedizinSchmerzzentrumUniversitätsklinikum Mannheim;Klinik für Anästhesiologie und Operative IntensivmedizinSchmerzzentrumUniversitätsklinikum Mannheim
Outcome results
None listed